Search
Search Results
##search.searchResults.foundPlural##
-
MONITORING THE RESPONSE TO TYROSINE KINASE INHIBITOR (TKI) TREATMENT IN CHRONIC MYELOID LEUKEMIA (CML)
4115PDF: 1576HTML: 9278Untitled: 306Untitled: 203Untitled: 190Untitled: 187Untitled: 204Untitled: 362 -
UPDATE ON CYTOMEGALOVIRUS INFECTION MANAGEMENT IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT RECIPIENTS A Consensus Document of the Spanish Group for Hematopoietic Transplantation and Cell Therapy (GETH-TC)
4295Suppl. Files: 1212PDF: 1126Html: 256 -
TP53-MUTATED MYELODYSPLASIA AND ACUTE MYELOID LEUKEMIA TP53 in MDS and AML
2272PDF: 1830HTML: 834 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3488PDF: 1332HTML: 2310Fi.1 Gritti.Rambaldi: 231 -
Guest Editor: G. Castaman GENE THERAPY FOR HEMOPHILIA: FACTS AND QUANDARIES IN THE 21ST CENTURY GENE THERAPY FOR HEMOPHILIA
2226PDF: 1974HTML: 522 -
TREATMENT OF ADVANCED SYSTEMIC MASTOCYTOSIS WITH MIDOSTAURIN: PRACTICAL GUIDANCE FOR OPTIMAL THERAPY AND MANAGEMENT Advanced systemic mastocytosis and midostaurin
1354PDF: 1082HTML: 425 -
CAR-T CELL THERAPY IN LARGE B CELL LYMPHOMA CAR-T; Large B Cell Lymphoma; Salvage Therapy,
3842PDF: 1531HTML: 343 -
IMMUNOLOGY OF TUBERCULOSIS
5742PDF: 2139HTML: 7359Untitled: 214 -
LENALIDOMIDE IN COMBINATION WITH DEXAMETHASONE IN ELDERLY PATIENTS WITH ADVANCED, RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND RENAL FAILURE
1361PDF: 939HTML: 1296fig 1A: 211figure1B: 180 -
MINIMAL RESIDUAL DISEASE IN ACUTE MYELOID LEUKEMIA OF ADULTS: DETERMINATION, PROGNOSTIC IMPACT AND CLINICAL APPLICATIONS.
5097PDF: 1350HTML: 1932Untitled: 209Untitled: 196 -
DRUG THERAPY IN THE PROGRESSED CML PATIENT WITH MULTI-TKI FAILURE
277789PDF: 1848HTML: 3897 -
NEW TREATMENTS FOR MYELODYSPLASTIC SYNDROMES
2064PDF: 1585HTML: 803 -
-
IMATINIB IN CHRONIC MYELOID LEUKEMIA: AN OVERVIEW
4948PDF: 2922HTML: 2341 -
TREATMENT RECOMMENDATIONS FOR CHRONIC MYELOID LEUKEMIA
3461PDF: 1518HTML: 4080 -
BLINATUMOMAB IN THE THERAPY OF ACUTE B-LYMPHOID LEUKEMIA BLINATUMOMAB and ALL
1722PDF: 1136HTML: 166 -
NON-SECRETORY MYELOMA: READY FOR A NEW DEFINITION?
3354PDF: 1747HTML: 1157 -
MANAGEMENT OF HBV INFECTION DURING IMMUNOSUPPRESIVE TREATMENT
889PDF: 497HTML: 1312 -
OPTIMIZING TREATMENT, MINIMIZING RISK: THERAPEUTIC DRUG MONITORING IN HEMATOLOGICAL MALIGNANCIES
1592PDF: 1850Suppl. Files: 181HTML: 107 -
-
MODERN IMMUNOTHERAPY OF ADULT B-LINEAGE ACUTE LYMPHOBLASTIC LEUKEMIA WITH MONOCLONAL ANTIBODIES AND CHIMERIC ANTIGEN RECEPTOR MODIFIED T CELLS
2362PDF: 1361HTML: 17203Bassan Fig.1: 159Bassan Fig.2: 261Bassan Fig.4: 153Fig.3: 225 -
EFFICACY OF VENETOCLAX COMBINED WITH AZACITIDINE IN ELDERLY PATIENTS WITH RELAPSED ACUTE MYELOID LEUKEMIA
1563PDF: 827Suppl. Files: 344Html: 151 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
3283PDF: 964HTML: 2991 -
-
Guest Editor: Pellegrino Musto BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA: APPROPRIATE SELECTION OF PATIENTS AND SEQUENCING BISPECIFIC ANTIBODIES AND CAR T IN MULTIPLE MYELOMA
1779PDF: 1318HTML: 606 -
THE PROTHROMBOTIC STATE ASSOCIATED WITH SARS-COV-2 INFECTION: PATHOPHYSIOLOGICAL ASPECTS COVID and Thrombosis
2319PDF: 851HTML: 446







